These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21463128)

  • 1. Response of hairy cell leukemia to bendamustine.
    Kreitman RJ; Arons E; Stetler-Stevenson M; Miller KB
    Leuk Lymphoma; 2011 Jun; 52(6):1153-6. PubMed ID: 21463128
    [No Abstract]   [Full Text] [Related]  

  • 2. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.
    Burotto M; Stetler-Stevenson M; Arons E; Zhou H; Wilson W; Kreitman RJ
    Clin Cancer Res; 2013 Nov; 19(22):6313-21. PubMed ID: 24097860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory?
    Cheson BD
    Leuk Res; 2014 Nov; 38(11):1267-8. PubMed ID: 25260826
    [No Abstract]   [Full Text] [Related]  

  • 4. Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.
    Montillo M; Tedeschi A; Gaidano G; Coscia M; Petrizzi VB; Orlandi E; Cascavilla N; Ghia P; Motta M; Gallamini A; Frustaci AM; Rossi D; De Paoli L; Nichelatti M; Morra E; Massaia M
    Haematologica; 2014 Sep; 99(9):e159-61. PubMed ID: 24972768
    [No Abstract]   [Full Text] [Related]  

  • 5. Bendamustine.
    Keating MJ; Bach C; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2008 Jun; 7(6):473-4. PubMed ID: 18511926
    [No Abstract]   [Full Text] [Related]  

  • 6. Bendamustine: a bridge to longer term solutions in heavily treated Hodgkin lymphoma.
    Moskowitz A
    Leuk Lymphoma; 2013 Nov; 54(11):2339-40. PubMed ID: 24093891
    [No Abstract]   [Full Text] [Related]  

  • 7. Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML.
    Giles FJ
    Leuk Lymphoma; 2007 Jun; 48(6):1064-6. PubMed ID: 17577766
    [No Abstract]   [Full Text] [Related]  

  • 8. Bendamustine and stem-cell mobilization: not so bad!
    Lopez JP; Shore TB
    Leuk Lymphoma; 2016 May; 57(5):993-4. PubMed ID: 26936530
    [No Abstract]   [Full Text] [Related]  

  • 9. Huge kidneys in a patient with chronic lymphocytic leukaemia.
    Esposito P; Libetta C; Rampino T; Gregorini M; Margiotta E; Dal Canton A
    Br J Haematol; 2015 Feb; 168(4):470. PubMed ID: 25384540
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
    Furukawa Y; Hiraoka N; Wada T; Kikuchi J; Kano Y
    Nihon Yakurigaku Zasshi; 2011 Jul; 138(1):26-32. PubMed ID: 21747206
    [No Abstract]   [Full Text] [Related]  

  • 11. Bendamustine can severely impair T-cell immunity against cytomegalovirus.
    Hosoda T; Yokoyama A; Yoneda M; Yamamoto R; Ohashi K; Kagoo T; Ueno H; Boku S; Yano T
    Leuk Lymphoma; 2013 Jun; 54(6):1327-8. PubMed ID: 23072371
    [No Abstract]   [Full Text] [Related]  

  • 12. Bendamustine is effective in T-cell prolymphocytic leukaemia.
    Herbaux C; Genet P; Bouabdallah K; Pignon JM; Debarri H; Guidez S; Betrian S; Leleu X; Facon T; Morschhauser F; Damaj G; Cazin B; Ysebaert L
    Br J Haematol; 2015 Mar; 168(6):916-9. PubMed ID: 25316212
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.
    Chacar C; Jabbour E; Ravandi F; Borthakur G; Kadia T; Estrov Z; Rios MB; Cortes J; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):197-200. PubMed ID: 22578814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Developmental history: bendamustine yesterday, today, tomorrow].
    Werner W; Herold M; Ruffert K; Merkle K; Brakhage A; Leoni L; Cheson BD
    Onkologie; 2013; 36 Suppl 1():2-10. PubMed ID: 23445757
    [No Abstract]   [Full Text] [Related]  

  • 15. MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab.
    Sadeghi N; Li HC
    Ann Hematol; 2018 Apr; 97(4):723-724. PubMed ID: 29285581
    [No Abstract]   [Full Text] [Related]  

  • 16. Bendamustine for treatment of chronic lymphocytic leukemia.
    Chang JE; Kahl BS
    Expert Opin Pharmacother; 2012 Jul; 13(10):1495-505. PubMed ID: 22663160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.
    Gil L; Kazmierczak M; Kroll-Balcerzak R; Komarnicki M
    Med Oncol; 2014 May; 31(5):944. PubMed ID: 24752517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report.
    Renfrow JJ; Detroye A; Chan M; Tatter S; Ellis T; McMullen K; Johnson A; Mott R; Lesser GJ
    J Neurooncol; 2012 May; 107(3):659-63. PubMed ID: 22249693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia.
    Kath R; Blumenstengel K; Fricke HJ; Höffken K
    J Cancer Res Clin Oncol; 2001 Jan; 127(1):48-54. PubMed ID: 11206271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
    Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
    Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.